Evidence map›Paper›PMID 32394351›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2020

Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression.

Patryk Krzeminski, Ramón García-Sanz, Norma C Gutiérrez

Abstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Patryk KrzeminskiHematology Department, University Hospital of Salamanca IBSAL, Salamanca, Spain. patrykk@usal.es.
Ramón García-SanzHematology Department, University Hospital of Salamanca IBSAL, Salamanca, Spain.
Norma C GutiérrezHematology Department, University Hospital of Salamanca IBSAL, Salamanca, Spain.
Centro de Investigación Biomédica en Red de Cáncer · ESCentro de Investigación del Cáncer · ESInstituto de Investigación Biomédica de Salamanca · ES

Funding

Institute of Health Carlos III/co-funding by FEDER PI16/01074Spanish Association for Cancer Research GCB120981SAN
6 · The paper itself

Abstract

purposeEpigenetic therapies have proven to be clinically effective in several hematological malignancies. Here, we aimed to evaluate the effect of a second-generation DNA demethylation agent, zebularine, on multiple myeloma (MM).

methodsWestern blot, ELISA, qRT-PCR, proliferation assays and cell transfection were used to investigate the mechanism of action of zebularine in MM.

resultsWe found that zebularine induced apoptosis and DNA demethylation in most of the MM cell lines tested. Its cytotoxic effect was associated with a time-dependent decrease in the level of c-Myc protein. Moreover, zebularine induced H2AX phosphorylation, a surrogate marker of DNA damage, in five out of eight MM cell lines tested.

conclusionsOur study revealed novel effects of zebularine on MM that may have potential implications for DNA methylation-based therapies.

Indexed as

Multiple MyelomaAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCytidineDNA MethylationHumansProto-Oncogene Proteins c-mycAntineoplastic AgentsCytidineMYC protein, humanProto-Oncogene Proteins c-mycpyrimidin-2-one beta-ribofuranosideBortezomibCell deathc-MycMethylationMyelomaZebularine

Identifiers

PMID32394351
PMCPMC12990685
OpenAlexW3024152068

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.